Leo puts target on Dupixent in US as FDA clears tralokinumab
pharmaphorum
DECEMBER 29, 2021
Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA has approved Leo Pharma’s rival antibody tralokinumab. It continues to grow strongly with Sanofi reporting a 53% rise in sales to more than $4.1 billion in the same year. billion in 2020. billion in 2020.
Let's personalize your content